HMGB1 and experimental autoimmune encephalomyelitis: Either through inhibition of HMGB1 or interaction with other still unknown molecules, EP has been found beneficial in the treatment of various inflammatory disorders, including myocardial ischemia-reperfusion injury (5), sepsis (6), pancreatitis (7), colitis (8), inflammatory arthritis (9), and experimental autoimmune encephalomyelitis (10).